Effectiveness of treatment of patients with systemic autoimmune diseases on the background of reactivation of persistent Epstein-Barr virus infection





systemic autoimmune diseases, Epstein-Barr virus, antiviral therapy


The article presents the study of effectiveness of inosine pranobex (IP) in patients with systemic autoimmune diseases (SAD) on the background of reactivation of persistent Epstein-Barr (EBV) infection. Among 380 patients with SAD (systemic lupus erythematosus, systemic vasculitides, rheumatoid arthritis, psoriasis), in 144 patients (37.9%) the reactivation of persistent EBV infection was detected through virus DNA identification using polymerase chain reaction (PCR) in three biological matrices (blood, saliva, scraping from the lesion site). 48 patients were receiving inosine pranobex at a dose of 50 mg/kg per day for three months. Treatment efficacy was controlled by studying the levels of expression of miR-146а, miR-155, miR EBV (BART-13 and BART-15), TLR9, the quantity of lymphocytes populations and subpopulations. After treatment, PCR results showed a decrease in viral replication in 66.7% of cases. The use of IP contributed to a significant decrease in the level of IgM, IgG specific antibodies, an increase in the level of expression of anti-inflammatory miR-146a, a decrease in the level of expression of pro-inflammatory miR-155 which may signify the strengthening of antiviral control. The study data demonstrated the decrease in the expression of miR EBV (BART-13 and BART-15) and TLR9 on the immunocompetent cells that can also be attributed to the criteria for IP effectiveness. The effectiveness of IP was also proved by the stabilization of cell mechanisms, namely the tendency to normalizing T and B cell populations, decrease in the number of natural killer cells and activated cells (CD25+, CD3+ HLA DR+). On the other hand, the number of lymphocytes with suppressor activity (CD4+25+) remained significantly high mitigating autoimmune aggression. The results of the study show that the use of IP for treating the acute phase of EBV infection contributed to the decrease of repliсative activity of the virus; suppressing the aggressiveness of autoimmune reactions. The decrease in the expression of miR EBV (BART-13 and BART-15) can be recommended as a criterion for the IP effectiveness; the decrease in the expression of TLR9 on immunocompetent cells –as a criterion for suppressing autoimmune reactions.


Svendsen AJ, Westergaard MCW, Draborg AH, Holst R, Kyvik KO, Jakobsen MA, Junker P, Houen G. Altered Antibody Response to Epstein-Barr Virus in Patients With Rheumatoid Arthritis and Healthy Subjects Predisposed to the Disease. A Twin Study. Front Immunol. 2021;12:650-713. doi: https://doi.org/10.3389/fimmu.2021.650713

Chougule D, Nadkar M, Rajadhyaksha A, Pandit-Shende P, Surve P, Dawkar N, Khadilkar P, Patward¬han M, Kaveri S, Ghosh K, Pradhan V. Association of clinical and serological parameters of systemic lupus erythematosus patients with Epstein-Barr virus antibody profile. J Med Virol. 2018;90(3):559-563. doi: https://doi.org/10.1002/jmv.24904

Cohen JI. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome. Front. Immunol. 2018;9:237. doi: https://doi.org/10.3389/fimmu.2018.00237

Draborg AH, Trier NH, Sternbæk L, Troelsen L, Larsen JL, Jacobsen S, Houen G. EBNA1 IgM-Based Discrimination Between Rheumatoid Arthritis Patients, Systemic Lupus Erythematosus Patients and Healthy Controls. Antibodies. 2019;8(2):35. doi: https://doi.org/10.3390/antib8020035

Coleman CB, Wohlford EM, Smith NA, King CA, Ritchie JA, Baresel PC, et al. Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphocytic cytokines. J Virol. 2015;89(4):2301-12. doi: https://doi.org/10.1128/JVI.03001-14

Faraldi M, Gomarasca M, Banfi G, Lombardi G. Free Circulating miRNAs Measurement in Clinical Settings: The Still Unsolved Issue of the Normalization. Adv Clin Chem. 2018;87:113-39. doi: https://doi.org/10.1016/bs.acc.2018.07.003

Ikeda T, Gion Y, Yoshino T, Sato Y. A review of EBV-positive mucocutaneous ulcers focusing on clinical and pathological aspects. J Clin Exp Hematop. 2019;59(2):64-71. doi: https://doi.org/10.3960/jslrt.18039

Zhang X, Ye Y, Fu M, Zheng B, Qiu Q, Huang Z. Implication of viral microRNAs in the genesis and diag¬nosis of Epstein Barr virus associated tumors (Review). Oncol Lett. 2019;18:3433-3442. doi: https://doi.org/10.3892/ol.2019.10713

Kaur P, Stoltzfus J, Yellapu V. Descriptive statistics. Int J Acad Med 2018;4:60-3. doi: https://doi.org/10.4103/IJAM.IJAM_7_18

Zubchenko S, Potemkina G, Chopyak V, Lishchuk-Yakymovych K. Correlation between miR-146a and miR-155 levels and concentration of cytokines in patients with allergopathy in chronic persistence of Epstein-Barr virus infection. Journal of Education, Health and Sport. 2019;9(10):230-245. doi: https://doi.org/10.5281/zenodo.3520935

Friedrich SK, Lang PA, Friebus-Kardash J, Duhan V, Bezgovsek J, Lang KS. Mechanisms of lymphatic system-specific viral replication and its potential role in autoimmune disease. Clin Exp Immunol. 2019;195(1):64-73. doi: https://doi.org/10.1111/cei.13241

Pender MP. Hypothesis: bipolar disorder is an Epstein–Barr virus‐driven chronic autoimmune disease – implications for immunotherapy. Clin Transl Immunol; 2020;9:e1116. doi: https://doi.org/10.1002/cti2.1116

Lyadova T, Ognivenko O, Rzhevska O, Zago¬rod¬neva O, Volobueva O. Prevalence of polymorphism of the TLR 9 type gene in patients with chronic forms of Eps¬tein-Barr virus infection. Georgian Med News. 2018;(276):112-117. doi: https://doi.org/10.26565/2313-6693-2018-35-06

Ball RJ, Avenell A, Aucott L, Hanlon P, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis. Arthritis Res Ther. 2015;17:274. doi: https://doi.org/10.1186/s13075-015-0755-6

Zhang SX, Ma XW, Li YF, Lai NL, Huang ZH, Fan K, Wang CH, Li XF. The Proportion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus: A Meta-Analysis. J Immunol Res. 2018;2018:7103219. doi: https://doi.org/10.1155/2018/7103219

Sepulveda-Toepfer JA, Pichler J, Fink K, Sevo M, Wildburger S, Mudde-Boer LC, Taus C, Mudde GC. TLR9-mediated activation of dendritic cells by CD32 targeting for the generation of highly immunostimulatory vaccines. Human Vaccines & Immunotherapeutics. 2019;15:1: 179-188. doi: https://doi.org/10.1080/21645515.2018.1514223

Yukawa M, Barski A, Salomonis N, Kaufman KM, Kottyan LC, Weirauch MT. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet. 2018 May;50(5):699-707. doi: https://doi.org/10.1038/s41588-018-0102-3




How to Cite

Lishchuk-Yakymovych K, Haiduchok I, Ischeykin K, Chopyak V. Effectiveness of treatment of patients with systemic autoimmune diseases on the background of reactivation of persistent Epstein-Barr virus infection. Med. perspekt. [Internet]. 2021Sep.30 [cited 2022Jan.26];26(3):47-54. Available from: http://journals.uran.ua/index.php/2307-0404/article/view/241936